Houston organizations announce 10 most promising life science startups

future of health care

Houston's medical innovation community congregated to discuss breakthrough innovations in health care. Photo via Getty Images

What startups are creating the future of health care? A Houston conference this week gathered to discuss.

The 10th annual Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship engaged thought leadership within the life science community with panels, discussions, and more. Additionally, 49 companies pitched their solutions across medical device, therapeutics, pharmaceuticals, and more to the crowd.

Austin-based Dynamic Light won the Michael E. DeBakey Memorial Life Science Award, established by BioHouston in honor of the groundbreaking Houston cardiovascular surgeon. The software company integrates with microscope or robotic systems to provide better visuals to surgeons and health care providers and reduce medical errors, radiation and costs. The award was presented by Ann Tanabe, CEO of BioHouston.

The event also named the 10 most promising life science companies selected by investors and presented by the Greater Houston Partnership. This year's selection included the following companies, in alphabetical order.

Ares Immunotherapy

Photo via Getty Images

Based in Cartersville, Georgia, Ares Immunotherapy uses a unique subset of T-cells for the treatment of solid tumors. According to the company, it is is preparing for a first in man trial in mesothelioma in 2023.

Corveus Medical

Photo courtesy of TMC

Houston-based Corveus Medical, which was formerly known as Caridian Medical, is a part of TMC's Biodesign program. The company was founded by Ishan Kamat, COO, and Tyler Melton, CEO.

"We are developing a novel, catheter-based device that performs a targeted sympathetic nerve ablation to treat heart failure," according to the company. "Our solution leverages the body’s natural mechanisms to bring fluid levels back to normal, giving physicians an effective treatment option, reducing costs for hospitals, and improving quality of life for the patient."

Drusolv Therapeutics

Photo via Pexels

Drusolv Therapeutics, based in Philadelphia, Pennsylvania, was founded out of Harvard University and been validated in a proof-of-concept clinical trial. The company's product, a novel reformulation of atorvastatin, is targeting age-related macular degeneration, or AMD, a serious eye disease. According to the company, it's a $4 billion a year, unmet need.

EMPIRI

Photo via jlabs.jnjinnovation.com

Houston-based EMPIRI is an early-stage biotechnology company currently focusing on precision oncology and utilizing automation for personal diagnosis. The company works out of JLABS @ TMC.

"Our proprietary 3D tissue culture method, E-slices, enables personalized drug response measurements from intact patient tissues," per the company. "E-slice has been clinically validated to accurately predict individual cancer patient responses to chemotherapies, targeted therapies, a immunotherapies."

Lapovations

Photo via Getty Images

Based in Fayetteville, Arkansas, Lapovations is working on technologies that improve laparoscopy.

"Our flagship product AbGrab is a single-use device that uses suction to lift the abdominal wall prior to closed insertion entry," according to the company. "Manually lifting can be difficult and unreliable, especially with obese patients or for clinicians with small hands."

Maxwell Biosciences

Photo by Chokniti Khongchum from Pexels

Austin-based Maxwell Biosciences is creating anti-infectives that inactivate a broad spectrum of viruses. The company's product, CLAROMERS, has seen success in its preclinical animal studies, as well as lab-grown human tissues. Maxwell is fueled by over $30 million in non-dilutive and government funding (e.g. DARPA, NIH, NIAID).

NeuraStasis

Image via neurastasis.com

Doctors have to respond quickly when treating ischemic stroke patients, and Houston-based NeuraStasis is working on a way to give them more time. Each minute a patient is waiting, irreparable damage is being done. The company's noninvasive solution uses electrical neurostimulation to preserve brain functionality. NeuraStasis is based in JLABS @ TMC.

Vena Medical

Image via venamed.ca

Canada medical device company Vena Medical is working on the "world's smallest camera" that is able to record inside veins and arteries to help physicians treat stroke.

Vivifi Medical

Photo courtesy of TMC

Houston-based Vivifi Medical, a Texas Medical Center Innovation company, is working to improve the quality of life of patients with Male Infertility and benign prostatic hyperplasia — 12 million men in the United States alone — by ending recurrency via suture-less laparoscopic technology.

XN Health

Image via xn-health.com

XN Health, based in Houston, has developed a novel approach to phrenic nerve stimulation to treat progression of ventilator induced diaphragm disfunction to help wean patients off the ventilator faster. The technology should speed up patient liberation times, shortening ICU stay, improve healthcare outcomes, and reduce health care costs.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

New certificate course trains a ready workforce as biotech companies in Pearland take off

Top of the Class

Biotech companies in Pearland are thriving, with big names such as Lonza, Millar Inc. Inc., and Abbott all experiencing tremendous growth in recent years.

The only challenge to this success is the increased demand for a faster workforce pipeline. Fortunately, the Pearland Economic Development Corporation (PEDC) has a solution.

PEDC has partnered with Alvin Community College (ACC) and Lonza to create a two-level Biotechnology Certificate Course designed to address the need for a better-equipped entry-level workforce.

This initiative offers two options to quickly train individuals for employment in the biotech field: Level 1, a six-week commitment for Biotech: Material Handler; and Level 2, a twelve-week commitment for Biotech: Lab Technician. Each level consists of 64 contact hours, with lectures delivered online and labs and assessments conducted on-site.

Alvin Community College is offering this course, which commenced on August 21, under its Continued Education and Workforce Development (CEWD) department. This department provides programs that incorporate current and new technical courses, training partnerships with businesses and industries, and other opportunities for individuals to acquire and upgrade skills or pursue personal enrichment.

Before this initiative, the region's two- or four-year programs were only graduating a dozen or so individuals. Early discussions focused on how to expedite workforce development through a local community college's certificate program. Alvin Community College was prepared to respond to the local workforce's needs.

PEDC played a pivotal role in establishing an advisory committee comprised of industry partners responsible for vetting the Biotechnology Certificate Course curriculum. Industry partners included the University of Houston Clear Lake (UHCL) at Pearland, Lonza, Millar Inc., Merit Medical, and the nonprofit organization BioHouston.

These partners are invaluable as plans continue to expand these certification programs.

Given the ever-increasing demand for a biotechnology workforce in the Pearland area, the future wish list includes expanding the certification program to other education partners.

For more information about the Biotechnology Certificate Program at Alvin Community College, visit this link.

Rice's new 'moonshot' initiative, VCs on Houston innovation, and more trending news

top stories

Editor's note:Another week has come and gone, and it's time to round up the top headlines from the past few days. Trending Houston tech and startup news on InnovationMap included the a roundup of key moments from Venture Houston, a unique new lab and new funding opportunities at Rice University, and more.

New biotech lab, accelerator emerges in Houston to speed up commercialization of life-saving cures

The first of Rice University's new moonshot initiatives, the Rice Biotech Launch Pad was announced on the 61st anniversary of President John F. Kennedy's address at Rice Stadium. Photo by Gustavo Raskosky/Rice University

A new initiative from Rice University is launching with an ambitious goal — to take biotech innovations from concept to clinical trials in five years or less.

The Rice Biotech Launch Pad is a newly announced initiative that will expedite Rice University's health and medical technology innovations. The accelerator, which will occupy 15,000 square feet of space on campus, will be funded through federal grants and donations.

“The Rice Biotech Launch Pad will ensure that our faculty and students have the skills, partnerships, tools and support to create technologies that can transform our city and the world,” Rice President Reginald DesRoches says in a press release. “More importantly, the accelerator will provide a pathway for these creations and discoveries to be turned into medical cures that significantly impact people’s lives. Rice researchers have been doing this for years. This development will allow them to do even more and at a quicker, more efficient pace.” Read more.

Houston VR training startup wins $90M contract with Air Force, Space Force

HTX Labs will supply immersive training technology and content to the Air Force and its Space Force military partner. Graphic courtesy of HTX Labs

HTX Labs has won a three-year, $90 million contract to provide immersive training capabilities for the Air Force and Space Force.

Under the new contract, which is set to end in September 2026, HTX Labs will supply immersive training technology and content to the Air Force and its Space Force military partner. The Houston company says the contract culminates more than five years of collaboration with the Air Force.

HTX Labs’ EMPACT cloud-based immersive training platform enables instructors and curriculum developers to create immersive lessons within EMPACT’s digital classrooms. HTX Labs says the Air Force and Space Force will retain full ownership of digital assets that are produced and will allow in-house updates of training materials. Read more.

Rice University launches research innovation grant program with VC fund in the works

Rice University has launched the One Small Step Grant program and has plans to establish the One Giant Leap VC fund. Photo courtesy of Rice University

Over 60 years ago at Rice University, President John F. Kennedy recommitted the country to the Space Race. Now, decades later, the university is announcing its commitment to moonshot innovators.

Rice University's Office of Innovation established the One Small Step Grant — named for Neil Armstrong's first words spoken from Tranquility Base just several years after JFK's speech at Rice — last month. The program will provide funding to faculty working on "promising projects with commercial potential," according to the website.

The grant initiative will provide as many as five awards a year, each with funding of up to $100,000. Applications, which are open now, are accepted on a rolling basis, and the university's Rice Investment Committee will review submissions on a quarterly basis. Read more.

Houston space tech company announces $20M equity investment

Intuitive Machines says the investment was made in exchange for stock and stock warrants. Photo courtesy of Intuitive Machines

An unidentified investor has pumped $20 million in equity into a Houston-based aerospace company.

Intuitive Machines says the investment was made in exchange for stock and stock warrants.

Intuitive Machines has earmarked the $20 million for general expenses and working capital to fuel “activity across key growth programs.” The company says the investment likely means it won’t need unused, previously disclosed equity financing of $50 million.

In one of those key growth programs, publicly traded Intuitive Machines is gearing up to launch three lunar landers in 2023 and 2024. Read more.

Founders, investors sound off on Houston's VC scene, energy innovation potential, and more

Hit the highlights of Venture Houston 2023 with these overheard moments from the event. Photo courtesy of HX Venture Fund

Last week, nearly 1,000 people convened in Houston to discuss venture capital activity, startups, and decarbonization, and the Houston factor among it all.

On September 7, Venture Houston hosted several keynote addresses and panels throughout the day's programming, and investors from across the country discussed with Houston-based startup and corporate leaders on topics from seed funding to cultivating an ecosystem.

The annual event, presented by HX Venture Fund, a fund of funds that deploys capital into VC funds with an interest in Houston, had one significant through line throughout the day, and it was Houston's role within innovation and the energy transition. Read more.

Houston startup with sustainable biotech solutions lands offtake arrangement with United Airlines

ready for takeoff

An innovative Houston company is celebrating a new deal with a global airline.

Cemvita Corp. announced a new offtake arrangement with United Airlines. Cemvita's first full-scale sustainable aviation fuel plant will provide up to 1 billion gallons of SAF to United Airlines. The 20-year contract specifies that Cemvita will supply up to 50 million gallons annually to United.

It's not the first collaboration Cemvita has had with the airline. Last year, United invested in the biotech company, which used the funding to open its Houston pilot plant.

“Since our initial investment last year, Cemvita has made outstanding progress, including opening their new pilot plant – an important step towards producing sustainable aviation fuel,” United Airlines Ventures President Michael Leskinen says in a news release. “United is the global aviation leader in SAF production investment, but we face a real shortage of available fuel and producers. Cemvita’s technology represents a path forward for a potentially significant supply of SAF and it’s our hope that this offtake agreement for up to one billion gallons is just the beginning of our collaboration.”

Founded in Houston in 2017 by brother-sister team Moji and Tara Karimi, Cemvita's biotechnology can mimic the photosynthesis process, turning carbon dioxide into feedstock. The company's SAF plan hopes to increase reliability of existing SAFs and lower impact of fuel creation.

“Biology is capable of truly amazing things,” Moji Karimi, CEO of Cemvita, says in the release. “Our team of passionate, pioneering, and persistent scientists and engineers are on a mission to create sustainable BioSolutions that redefine possibilities.”

“We are thrilled to partner with United Airlines in working towards transforming the aviation industry and accelerating the energy transition,” he continues. “This agreement featuring our unique SAF platform is a major milestone towards demonstrating our journey to full commercialization.”

Earlier this year, United, which was reportedly the first airline to announce its goal of net zero carbon emissions by 2050, launched its UAV Sustainable Flight FundSM. The fund, which named Cemvita to its inaugural group of portfolio companies, has raised over $200 million, as of this summer.

Moji and Tara Karimi co-founded Cemvita in 2017. Photo courtesy of Cemvita

------

This article originally ran on EnergyCapital.

View All Listings